Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-001038-32
    Sponsor's Protocol Code Number:8-55-58102-002
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2012-07-19
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-001038-32
    A.3Full title of the trial
    A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AFTER A FIRST LINE DOCETAXEL BASED CHEMOTHERAPY
    Estudio de prueba de concepto, aleatorizado, doble ciego y controlado con placebo, de terapia de mantenimiento con tasquinimod, en pacientes con cáncer de próstata metastásico resistente a la castración, que no presentan progresión tras primera línea con quimioterapia basada en docetaxel
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AFTER A FIRST LINE DOCETAXEL BASED CHEMOTHERAPY
    Estudio de prueba de concepto, aleatorizado, doble ciego y controlado con placebo, de terapia de mantenimiento con tasquinimod, en pacientes con cáncer de próstata metastásico resistente a la castración, que no presentan progresión tras primera línea con quimioterapia basada en docetaxel
    A.4.1Sponsor's protocol code number8-55-58102-002
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIpsen Pharma
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportIpsen Pharma
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIpsen Pharma
    B.5.2Functional name of contact pointVP Worldwide Clinical Development
    B.5.3 Address:
    B.5.3.1Street Address65 quai Georges Gorse
    B.5.3.2Town/ cityBoulogne-Billancourt
    B.5.3.3Post code92100
    B.5.3.4CountryFrance
    B.5.6E-mailct-application@ipsen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametasquinimod
    D.3.2Product code ABR-215050
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtasquinimod
    D.3.9.1CAS number 254964-60-8
    D.3.9.2Current sponsor codeABR-215050
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number0.25 to 1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    maintenance therapy in metastatic Castrate Resistant Prostate Cancer patients who are not progressing under/after a first line docetaxel based chemotherapy
    Terapia de mantenimiento en cáncer de próstata metastásico resistente a la castración que no progresa durante o tras primera línea de quimioterapia basada en docetaxel
    E.1.1.1Medical condition in easily understood language
    maintenance therapy in metastatic Castrate Resistant Prostate Cancer patients who are not progressing under/after a first line docetaxel based chemotherapy
    Terapia de mantenimiento en cáncer de próstata metastásico resistente a la castración que no progresa durante o tras primera línea de quimioterapia basada en docetaxel
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the clinical efficacy (i.e. radiological progression free survival [PFS]) of tasquinimod maintenance therapy with placebo in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have not progressed after a first line docetaxel based chemotherapy.
    Comparar la eficacia clínica (es decir, la supervivencia libre de progresión radiológica [SLP]) del tratamiento de mantenimiento con tasquinimod en comparación con placebo en pacientes con cáncer de próstata metastásico resistente a la castración (CPRCm) que no hayan experimentado progresión después de quimioterapia de primera línea con docetaxel.
    E.2.2Secondary objectives of the trial
    To further evaluate the safety profile of tasquinimod
    To compare other clinical benefits (such as overall survival, PFS on next-line therapy [PFS 2] and symptoms) of tasquinimod with placebo
    To evaluate the impact of tasquinimod on health related quality of life (QoL)
    To further characterise the pharmacokinetics (PK) of tasquinimod using a population approach.
    Evaluar con más detalle el perfil de seguridad de tasquinimod
    Comparar otros beneficios clínicos (tales como la supervivencia global, la SLP con el tratamiento de la siguiente línea [SLP 2] y los síntomas) de tasquinimod en comparación con placebo
    Evaluar el impacto de tasquinimod en la calidad de vida (CdV) relacionada con la salud
    Caracterizar con mayor detalle la farmacocinética (FC) de tasquinimod utilizando un enfoque poblacional.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    All patients must fulfil the following criteria to participate in the study:
    (1)Has provided written informed consent
    (2)Histologically documented prostate cancer with evidence of metastatic disease on radiological evaluation, with or without symptoms (defined according to the brief pain inventory [BPI] scale, with use of analgesics or narcotics)
    (3)Has received a first line docetaxel based chemotherapy of 75 mg/m² (as starting dose) every 3 weeks schedule of administration with corticosteroids for a minimum of 6 cycles. Any combination with investigational or non investigational agent is prohibited
    (4)Male aged ?18 years old
    (5)Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    (6)Docetaxel-related adverse effects must have been resolved to NCI-CTCAE v4.03 Grade ?1. Chemotherapy-induced alopecia and Grade 2 peripheral neuropathy are allowed
    (7)No progressive disease at the end of docetaxel treatment defined according to RECIST criteria, no new lesion(s) assessed by bone scan and no elevated PSA for the three last tests (with the first two PSA values above or equal to the third PSA value). The time between each PSA test should be preferably at least 14 days, however a minimum of 7 days is acceptable. The third value will be used for study selection
    (8)Last dose of docetaxel administered between 21 and 42 days before randomisation
    (9)Chemical or surgical castration verified by levels of serum testosterone ?50 ng/dL (1.75 nmol/L)
    (10)A life expectancy of at least 12 weeks in the judgment of the Investigator
    (11)The following laboratory values within 7 days prior to randomisation:
    ?Haematology
    -Absolute granulocytes ?1.5 x 109/L
    -Platelets ?100 x 109/L
    -Haemoglobin ?9 g/dL transfusions allowed, epoetin alfa allowed only if last administration >2 weeks before randomisation
    ?Biochemistry
    -Bilirubin ?1.5 x upper limit of normal (ULN)
    -Serum creatinine ?1.5 x ULN or calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula ?60 mL/min
    -Alanine aminotransferase/ aspartate aminotransferase ?3 x ULN (?5 x ULN if liver metastases present)
    (12)If sexually active with partner of childbearing potential, patient will agree to use adequate contraceptive method (barrier contraceptive with spermicide) while receiving study treatment and until 14 days after the stop of study treatment or have been previously vasectomised
    (13)Able to swallow and retain oral drug
    (14)Able to adhere to the study visit schedule and other protocol requirements
    (15)Must be available for treatment, evaluation assessments and follow-up at the study centres
    (16)Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and to cooperate with the Investigator and to comply with the requirements of the entire study.
    (1) Otorgar su consentimiento informado por escrito
    (2) Tener cáncer de próstata confirmado histológicamente con signos de enfermedad metastásica en la evaluación radiológica, con o sin síntomas (definidos mediante el Brief Pain Inventory [BPI] y el uso de analgésicos u opiáceos)
    (3) Haber recibido quimioterapia de primera línea con docetaxel 75 mg/m² (como dosis inicial) cada 3 semanas según el calendario de administración, con corticosteroides, durante un mínimo de 6 ciclos. Se prohíbe cualquier combinación con productos experimentales o autorizados
    (4) Varón de ? 18 años de edad
    (5) Estado funcional de 0 o 1 del Eastern Cooperative Oncology Group (ECOG)
    (6) Los acontecimientos adversos relacionados con docetaxel deberán haberse resuelto hasta un grado ? 1 de los CTCAE del NCI v4.03. Se permite la alopecia inducida por la quimioterapia y la neuropatía periférica de grado 2
    (7) Sin progresión de la enfermedad al final del tratamiento con docetaxel, definida según criterios RECIST, sin lesiones nuevas evaluadas mediante gammagrafía ósea y sin elevación del PSA en las tres últimas pruebas (siendo los dos primeros valores del PSA mayores o iguales que el tercer valor del PSA). El tiempo entre cada prueba del PSA debe ser preferiblemente de 14 días al menos, aunque es aceptable un mínimo de 7 días. El tercer valor se utilizará para la selección del estudio
    (8) Última dosis de docetaxel administrada entre 21 y 42 días antes de la aleatorización
    (9) Castración química o quirúrgica, verificada mediante niveles de testosterona sérica ? 50 ng/dl (1,75 nmol/l)
    (10) Esperanza de vida de al menos 12 semanas a criterio del investigador
    (11) Los siguientes valores analíticos en el plazo de 7 días anteriores a la aleatorización:
    ? Hematología
    - Cifra absoluta de granulocitos ? 1,5 x 109/l
    - Plaquetas ? 100 x 109/l
    - Hemoglobina ? 9 g/dl, se permite administrar transfusiones, se permite administrar epoetina alfa solo si la última administración tuvo lugar > 2 semanas antes de la aleatorización
    ? Bioquímica
    - Bilirrubina ? 1,5 x límite superior de normalidad (LSN)
    - Creatinina sérica ? 1,5 x LSN o aclaramiento de creatinina (CrCl) calculado utilizando la fórmula de Cockcroft-Gault ? 60 ml/min
    - Alanina aminotransferasa/aspartato aminotransferasa ? 3 x LSN (? 5 x LSN en caso de metástasis hepáticas)
    (12) Si el paciente es sexualmente activo con pareja en edad fértil, deberá aceptar utilizar un método anticonceptivo adecuado (anticonceptivo de barrera con espermicida) durante el tratamiento del estudio y hasta 14 días después de la suspensión del tratamiento del estudio, o haberse sometido a una vasectomía con anterioridad
    (13) Capaz de tragar y retener la medicación oral
    (14) Capaz de cumplir el calendario de visitas y los demás requisitos del protocolo
    (15) Disponibilidad para el tratamiento, las evaluaciones y el seguimiento en los centros del estudio
    (16) Capaz de comprender por completo la naturaleza y el objetivo del estudio, incluidos los posibles riesgos y efectos secundarios, y colaborar con el investigador y cumplir los requisitos de todo el estudio
    E.4Principal exclusion criteria
    A patient will not be included in the study if he:
    (1)Has concurrent use of other anticancer agents or treatments, with the following exceptions: ongoing treatment with luteinising hormone-releasing hormone agonists or antagonists, denosumab or bisphosphonate (e.g. zoledronic acid) is permitted if started ?4 weeks prior to Screening. Ongoing treatment should be kept at a stable dose regimen
    (2)Has ongoing treatment with warfarin
    (3)Had prior radiation therapy since starting docetaxel. Exceptions may be made for palliative non-myelosuppressive radiation therapy administered more than 2 weeks prior to randomisation
    (4)Had prior strontium, samarium or radium therapy or prior treatment with tasquinimod, or any agents with antiangiogenic properties
    (5)Has ongoing treatment with corticosteroids at >10 mg/day prednisolone equivalent
    (6)Has prostate cancer pain that warrants the initiation of radiotherapy or chemotherapy
    (7)Has known hypersensitivity to the study treatment, to any of its excipients or treatments with a similar chemical structure
    (8)Has ongoing treatment with cytochrome P450 (CYP) 1A2 or CYP3A4 metabolised drug substance with narrow therapeutic range at the start of study treatment
    (9)Has a systemic exposure to ketoconazole or other strong CYP3A4 isozyme inhibitors or inducers within 14 days prior to the start of study treatment. Systemic exposure to amiodarone is not permitted within 1 year prior to the start of study treatment
    (10)Has simultaneous participation in any other study involving treatment with investigational drugs or device or has received treatment with investigational drugs less than 4 weeks prior to randomisation
    (11)Has myocardial infarction, percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass graft, New York Heart Association (NYHA) class III/IV congestive heart failure, cerebrovascular accident, transient ischaemic attack, or limb claudication at rest, within 6 months prior to randomisation and ongoing symptomatic dysrhythmias, unstable angina, uncontrolled hypertension and uncontrolled atrial or ventricular arrhythmias
    (12)Has history of pancreatitis
    (13)Has known brain or epidural metastases. Patients with previous medullary cord compression without any neurological deficit could be included
    (14)Has known positive serology for human immunodeficiency virus
    (15)Has chronic hepatitis with advanced, decompensated hepatic disease, cirrhosis of the liver, history of a chronic viral hepatitis or known viral hepatitis carrier (patients who have recovered from hepatitis will be permitted to enter the study)
    (16)Has active tuberculosis (TB), or with known, untreated latent TB. Country-specific TB therapy should have been given for at least 30 days prior to the start of study treatment and patient should intend to complete the entire course of that therapy
    (17)Has any condition, including other active or latent infections, medical or psychiatric conditions, or the presence of clinically significant laboratory abnormalities, which could confound the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study
    (18)Should not participate in the study in the opinion of the Investigator
    (19)Is currently receiving immunosuppressive therapy
    (20)Has a history of major surgery 4 weeks prior to randomisation, or has an incompletely healed surgical incision
    (21)Has a history of other malignancies, except adequately treated non-melanoma skin cancer or other solid tumours curatively treated, without evidence of disease for >5 years
    (22)Is deprived of his freedom or rights by virtue of an order issued either by any judicial or administrative authorities, is unable to express his consent, or is committed to a health institution for reasons other than the study
    (23)Has a history of, or known current, problems with drug or alcohol abuse
    (24)Has any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
    (1) Utiliza simultáneamente otros fármacos o tratamientos antineoplásicos, con las siguientes excepciones: se permite el tratamiento en curso con agonistas o antagonistas de la hormona liberadora de gonadotropinas, denosumab o bisfosfonatos (p. ej., ácido zoledrónico) si ha comenzado ? 4 semanas antes de la Selección. El tratamiento en curso debe mantenerse a una dosis estable
    (2) Recibe tratamiento en curso con warfarina.
    (3) Ha recibido radioterapia previa desde el comienzo de docetaxel. Pueden hacerse excepciones si se administra como radioterapia paliativa no mielosupresora más de 2 semanas antes de la aleatorización
    (4) Ha recibido anteriormente tratamiento con estroncio, samario o radio o con tasquinimod o cualquier fármaco con propiedades antiangiogénicas
    (5) Continúa el tratamiento con corticosteroides en dosis > 10 mg/día equivalentes a prednisolona
    (6) Tiene dolor relacionado con el cáncer de próstata que justifica el inicio de la radioterapia o quimioterapia
    (7) Tiene hipersensibilidad conocida al tratamiento del estudio, a cualquiera de los excipientes o tratamientos con estructura química similar
    (8) Continúa el tratamiento con principios activos metabolizados por el citocromo P450 (CYP) 1A2 o CYP3A4 con un estrecho margen terapéutico al inicio del tratamiento del estudio
    (9) Tiene exposición sistémica a ketoconazol u otros inhibidores o inductores potentes de la isoenzima 3A4 del citocromo P450 en los 14 días anteriores al comienzo del tratamiento del estudio. No se permite la exposición sistémica a amiodarona en el año previo al inicio del tratamiento del estudio
    (10) Ha participado simultáneamente en otro estudio que consiste en el tratamiento con fármacos o dispositivos en investigación o ha recibido tratamiento con fármacos en investigación menos de 4 semanas antes de la aleatorización
    (11) Tiene antecedentes de infarto de miocardio, intervención coronaria percutánea, síndrome coronario agudo, injerto de derivación aortocoronario, insuficiencia cardíaca congestiva de clase III/IV de la New York Heart Association (NYHA), accidente cerebrovascular, accidente isquémico transitorio o claudicación de las extremidades en reposo, en los 6 meses previos a la aleatorización, o presencia actual de arritmias sintomáticas, angina inestable, hipertensión no controlada y arritmias auriculares o ventriculares no controladas.
    (12) Tiene antecedentes de pancreatitis.
    (13) Se le han diagnosticado metástasis cerebrales o epidurales. Podrían participar los pacientes con compresión medular previa sin ningún otro déficit neurológico.
    (14) Tiene serología positiva conocida para el virus de la inmunodeficiencia humana
    (15) Tiene hepatitis crónica con hepatopatía avanzada y descompensada o cirrosis hepática, o antecedentes de hepatitis viral crónica, o portador conocido de hepatitis viral (podrán participar los pacientes que se hayan recuperado de una hepatitis).
    (16) Tiene tuberculosis activa (TB), o TB latente diagnosticada y no tratada. Deberá haber recibido el tratamiento de la TB específico de cada país durante al menos 30 días antes del inicio del tratamiento del estudio, y el paciente debe tener previsto completar todo el ciclo del mismo
    (17) Tiene alguna afección, incluidas otras infecciones activas o latentes, enfermedades médicas o psiquiátricas, o presenta anomalías analíticas clínicamente significativas, que podrían ser un factor de confusión en la interpretación de los datos del estudio o que supongan para el paciente un riesgo inaceptable si participa en el estudio
    (18) No debe participar en el estudio en opinión del investigador
    (19) Actualmente está recibiendo tratamiento inmunosupresor
    (20) Tiene antecedentes de cirugía mayor en las 4 semanas anteriores a la aleatorización, o tiene una incisión quirúrgica cicatrizada de forma incompleta
    (21) Tiene antecedentes de otras neoplasias malignas, excepto el cáncer de piel no melanoma tratado adecuadamente u otros tumores sólidos tratados de forma curativa, sin signos de enfermedad durante > 5 años
    (22) Está privado de libertad o derechos en virtud de una orden emitida por cualquier autoridad judicial o administrativa, no es capaz de expresar su consentimiento o mantiene un compromiso con una institución sanitaria por motivos distintos a los del estudio
    (23) Tiene antecedentes o problemas actuales con abuso de sustancias o alcohol.
    (24) Tiene una enfermedad mental que impide al sujeto comprender la naturaleza, el alcance y las posibles consecuencias del estudio, o hay indicios de una posible falta de cooperación.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is radiological PFS including skeleton related events, defined as the time from the date of randomisation to the date of radiological progression or death due to any cause.
    El criterio principal de valoración es la SLP radiológica, incluidos episodios óseos, definida como el tiempo desde la fecha de aleatorización hasta la fecha de la progresión radiológica o la muerte por cualquier causa.
    E.5.1.1Timepoint(s) of evaluation of this end point
    assessment every 8 weeks until radiological progression
    Evaluación cada 8 semanas hasta progresión radiológica.
    E.5.2Secondary end point(s)
    ? Overall survival, defined as the time from randomisation to death due to any cause
    ? Symptomatic PFS, defined as the time from the date of randomisation to the date of symptomatic progression or death due to prostate cancer, whichever occurs first (symptomatic progression as assessed by Pain BPI and analgesic use)
    ? Time from randomisation to further treatment for prostate cancer
    ? QoL measured by the Functional Assessment of Cancer Therapy Prostate Module (FACT P) questionnaire and by the EuroQol-5 Dimension QoL Instrument (EQ 5D)
    ? PK measurements of tasquinimod.
    ? PFS on next-line therapy (PFS 2)
    ? Complete physical examination including the evaluation of performance status (ECOG), vital signs measurements and body weight
    ? Electrocardiogram findings
    ? Clinical laboratory assessments
    ? Adverse events.
    ? Supervivencia global, definida como el tiempo desde la aleatorización hasta la muerte por cualquier causa.
    ? SLP sintomática, definida como el tiempo desde la fecha de aleatorización hasta la fecha de la progresión sintomática o muerte por cáncer de próstata, lo que suceda primero (progresión sintomática evaluada según el inventario BPI de dolor y el uso de analgésicos)
    ? Tiempo desde la aleatorización hasta otro tratamiento para el cáncer de próstata
    ? CdV medida mediante el módulo de próstata del cuestionario de evaluación funcional del tratamiento del cáncer Functional Assessment of Cancer Therapy Prostate Module (FACT-P) y el instrumento de CdV EuroQol de 5 dimensiones (EQ-5D)
    ? Mediciones de FC de tasquinimod.
    ? SLP con el tratamiento de la siguiente línea (SLP 2)
    ? Exploración física completa, incluida la evaluación del estado funcional (ECOG), determinaciones de las constantes vitales y peso corporal
    ? Resultados del electrocardiograma
    ? Evaluaciones analíticas
    ? Acontecimientos adversos.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please see schedule of assessment (pages 10-12 of the protocol)
    Por favor referirse al calendario de evaluaciones (páginas 11 y 12 del protocolo)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA50
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Bulgaria
    Czech Republic
    Denmark
    France
    Germany
    Hungary
    Italy
    Latvia
    Lithuania
    Poland
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will be considered to have finished (end of study) when 80% of the patients have died or when all patients have been followed up for 2 years, whichever occurs last.
    El estudio se considerará finalizado (fin de estudio) cuando el 80 % de los pacientes haya fallecido o cuando todos los pacientes hayan sido sometidos a seguimiento durante 2 años, lo que suceda más tarde.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 70
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 70
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 140
    F.4.2.2In the whole clinical trial 140
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Treatment after the subject has ended the participation in the trial will be let to investigator's judgement.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-09-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-09-04
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:48:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA